Discovery of serum protein biomarkers in drug-free patients with major depressive disorder

[1]  S. Bahn,et al.  Targeted Multiplexed Selected Reaction Monitoring Analysis Evaluates Protein Expression Changes of Molecular Risk Factors for Major Psychiatric Disorders , 2014, The international journal of neuropsychopharmacology.

[2]  J. Cooper,et al.  Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. , 2014, The international journal of neuropsychopharmacology.

[3]  Brendan MacLean,et al.  MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments , 2014, Bioinform..

[4]  Rüdiger Schweigreiter,et al.  Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain☆ , 2014, Neurobiology of Aging.

[5]  Eric W Deutsch,et al.  Using PeptideAtlas, SRMAtlas, and PASSEL: Comprehensive Resources for Discovery and Targeted Proteomics , 2014, Current protocols in bioinformatics.

[6]  R. Brook,et al.  Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials , 2014, Journal of the American Heart Association.

[7]  Garth L. Maker,et al.  A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  Orrin Devinsky,et al.  Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence , 2013, Journal of Neuroinflammation.

[9]  J A Bilello,et al.  Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study , 2013, Molecular Psychiatry.

[10]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[11]  J. M. Ramsey,et al.  Molecular Sex Differences in Human Serum , 2012, PloS one.

[12]  P. Xie,et al.  Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. , 2012, The international journal of neuropsychopharmacology.

[13]  Yong Ho Bae,et al.  Molecular insights on context-specific role of profilin-1 in cell migration , 2012, Cell adhesion & migration.

[14]  S. Selek,et al.  No effect of antidepressant treatment on elevated serum ceruloplasmin level in patients with first-episode depression: a longitudinal study. , 2012, Archives of medical research.

[15]  W Gardner,et al.  Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression , 2012, Translational Psychiatry.

[16]  Ronald S Duman,et al.  Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology , 2011, Neuropsychopharmacology.

[17]  Preben Bo Mortensen,et al.  Absolute risk of suicide after first hospital contact in mental disorder. , 2011, Archives of general psychiatry.

[18]  D. Sanchez,et al.  Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat‐challenged dopaminergic systems , 2011, Glia.

[19]  Karl Mechtler,et al.  General statistical modeling of data from protein relative expression isobaric tags. , 2011, Journal of proteome research.

[20]  C. Furberg,et al.  A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk , 2011, Circulation. Cardiovascular quality and outcomes.

[21]  Ruedi Aebersold,et al.  On the development of plasma protein biomarkers. , 2011, Journal of proteome research.

[22]  H. Saya,et al.  Proteome profiling reveals gender differences in the composition of human serum , 2010, Proteomics.

[23]  L. Niskanen,et al.  Elevated depressive symptoms and compositional changes in LDL particles in middle-aged men , 2010, European Journal of Epidemiology.

[24]  B. Searle.  Scaffold: A bioinformatic tool for validating MS/MS‐based proteomic studies , 2010, Proteomics.

[25]  Edward T. Bullmore,et al.  Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections , 2010, PloS one.

[26]  Daniel Martins-de-Souza,et al.  The role of proteomics in depression research , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[27]  M. Benn.  Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. , 2009, Atherosclerosis.

[28]  Michael P. Cusack,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[29]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[30]  J. Nurnberger,et al.  Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis , 2009, Molecular Psychiatry.

[31]  L. Shaw,et al.  Depression, the Metabolic Syndrome and Cardiovascular Risk , 2008, Psychosomatic medicine.

[32]  M. Tsuang,et al.  Convergent Functional Genomics of bipolar disorder: From animal model pharmacogenomics to human genetics and biomarkers , 2007, Neuroscience & Biobehavioral Reviews.

[33]  A. Horrevoets.  Profilin-1: an unexpected molecule linking vascular inflammation to the actin cytoskeleton. , 2007, Circulation research.

[34]  A. Kazlauskas,et al.  Attenuated Expression of Profilin-1 Confers Protection From Atherosclerosis in the LDL Receptor–Null Mouse , 2007, Circulation research.

[35]  H. Akiyama,et al.  Expression analysis of actin-related genes as an underlying mechanism for mood disorders. , 2007, Biochemical and biophysical research communications.

[36]  Christine A. Miller,et al.  Efficient Fractionation and Improved Protein Identification by Peptide OFFGEL Electrophoresis*S , 2006, Molecular & Cellular Proteomics.

[37]  J. Meador-Woodruff,et al.  Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia , 2006, Schizophrenia Research.

[38]  A. Sarandol,et al.  Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  Tom Fawcett,et al.  An introduction to ROC analysis , 2006, Pattern Recognit. Lett..

[40]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[41]  Bruce S. McEwen,et al.  Metabolism, mood and cognition in aging: The importance of lifestyle and dietary intervention , 2005, Neurobiology of Aging.

[42]  J. Borén,et al.  Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis , 2005, Journal of internal medicine.

[43]  V. Vassiliev,et al.  Ceruloplasmin in neurodegenerative diseases , 2005, Brain Research Reviews.

[44]  Y. Ahn,et al.  Validity and Reliability of the Korean Version of the Hamilton Depression Rating Scale(K-HDRS) , 2005 .

[45]  James Franklin.  The elements of statistical learning: data mining, inference and prediction , 2005 .

[46]  J. Bertolini,et al.  Therapeutic potential of vitamin D-binding protein. , 2004, Trends in biotechnology.

[47]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[48]  J. Sutcliffe,et al.  From pharmacotherapy to pathophysiology: emerging mechanisms of apolipoprotein D in psychiatric disorders. , 2003, Current molecular medicine.

[49]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[50]  H. Manji,et al.  Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression , 2003, Biological Psychiatry.

[51]  V. Parikh,et al.  Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome , 2002, Schizophrenia Research.

[52]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[53]  Jean-Pierre Julien,et al.  Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.

[54]  Paul J. Harrison,et al.  The neuropathology of primary mood disorder. , 2002, Brain : a journal of neurology.

[55]  M. Barrot,et al.  Neurobiology of Depression , 2002, Neuron.

[56]  M. Reindl,et al.  Increased intrathecal production of apolipoprotein D in multiple sclerosis , 2001, Journal of Neuroimmunology.

[57]  J. Kelsoe,et al.  Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. , 2000, Physiological genomics.

[58]  M. Fava,et al.  Major Depressive Disorder , 2000, Neuron.

[59]  P. White,et al.  The Multifunctional Properties and Characteristics of Vitamin D-binding Protein , 2000, Trends in Endocrinology & Metabolism.

[60]  A. Nakamura,et al.  Increased lipid peroxidation in the brains of aceruloplasminemia patients , 2000, Journal of the Neurological Sciences.

[61]  S. Liebhaber,et al.  Vitamin D-binding Protein Gene Transcription Is Regulated by the Relative Abundance of Hepatocyte Nuclear Factors 1α and 1β* , 1998, The Journal of Biological Chemistry.

[62]  John A. Rice,et al.  A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. , 1998, Archives of general psychiatry.

[63]  B. Barraclough,et al.  Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia , 1998, British Journal of Psychiatry.

[64]  G. Blair-West,et al.  Down‐rating lifetime suicide risk in major depression , 1997, Acta psychiatrica Scandinavica.

[65]  A. Rush,et al.  The Inventory of Depressive Symptomatology (IDS): psychometric properties , 1996, Psychological Medicine.

[66]  P. McGuffin,et al.  The Genetics of Depression and Manic-Depressive Disorder , 1989, British Journal of Psychiatry.

[67]  A. Beck,et al.  An inventory for measuring clinical anxiety: psychometric properties. , 1988, Journal of consulting and clinical psychology.

[68]  P. Alaupovic,et al.  Isolation and partial characterization of apolipoprotein D: A new protein moiety of the human plasma lipoprotein system , 1973, FEBS letters.

[69]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[70]  J. Tolivia,et al.  Oxidative stress induces apolipoprotein D overexpression in hippocampus during aging and Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[71]  J. Seok,et al.  Reliability and Validity of the Korean Version of Inventory for Depressive Symptomatology , 2012 .

[72]  E. Deutsch.  The PeptideAtlas Project , 2010, Proteome Bioinformatics.

[73]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[74]  H. Zhu,et al.  Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene , 2005, Amino Acids.

[75]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .